Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.36 |
| ▸ | DRD2 | P14416 | 2/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.34 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.34 |
| ▸ | RAF1 | P04049 | 1/20 | 0.34 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.34 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.34 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL193729 | 0.98 | HTR2C (0.36) | HTR2CDRD2HTR2AKCNH2FFAR1 | |
| Hydrochloric Acid SCHEMBL30836067 | 0.82 | HTR2C (0.42) | HTR2CHTR2AKCNH2HTR2B | |
| Hydrochloric Acid SCHEMBL31556498 | 0.72 | HTR2A (0.45) | HTR2CDRD2HTR2AKCNH2HTR2B | |
| SCHEMBL2597848 | 0.72 | SLC6A1 (0.42) | PAX8 | |
| SCHEMBL4797241 | 0.69 | DRD2 (0.33) | DRD2DRD3 | |
| SCHEMBL9497272 | 0.69 | FFAR1 (0.41) | FFAR1FFAR4PAX8 | |
| SCHEMBL9497279 | 0.69 | FFAR1 (0.41) | FFAR1FFAR4PAX8 | |
| SCHEMBL25305280 | 0.68 | HTR3A (0.53) | HTR2CDRD2HTR2AKCNH2DRD3 | |
| SCHEMBL2145333 | 0.68 | HTR3A (0.53) | HTR2CDRD2HTR2AKCNH2DRD3 | |
| SCHEMBL24127465 | 0.68 | HTR3A (0.53) | HTR2CDRD2HTR2AKCNH2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163775-B2 | Allosteric modulators of metabotropic glutamate receptors | ADDEX PHARMA SA (CH) | 2012-04-24 | — | — | US | disclosed |
| US-20120022108-A1 | ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA SA (CH) | 2012-01-26 | — | — | US | disclosed |
| EP-2030970-B1 | Allosteric modulators of metabotropic glutamate receptors | ADDEX PHARMACEUTICALS SA (CH) | 2012-01-04 | — | — | EP | disclosed |
| US-8030331-B2 | Allosteric modulators of metabotropic glutamate receptors | ADDEX PHARMA SA (CH) | 2011-10-04 | — | — | US | disclosed |
| US-20110112143-A1 | ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA SA (CH) | 2011-05-12 | — | — | US | disclosed |
| US-7834035-B2 | Schizophrenia and related disorders; positive allosteric modulators of mGluR5; {3-[3-(4-Methoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-phenyl-methanone for example; compounds are all contain a 5-(1-carbonylpiperidin-3-yl)-1,2,4-oxadiazole moiety | ADDEX PHARMA SA (CH) | 2010-11-16 | — | — | US | disclosed |
| EP-2030970-A1 | Allosteric modulators of metabotropic glutamate receptors | ADDEX Pharma S.A. (CH) | 2009-03-04 | — | — | EP | disclosed |
| EP-1685105-B1 | ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA SA (CH) | 2008-10-15 | — | — | EP | disclosed |
| US-20070219187-A1 | Allosteric Modulators of Metabotropic Glutamate Receptors | ADDEX PHARMA SA (CH) | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219187-A1 | Allosteric Modulators of Metabotropic Glutamate Receptors | GRM5, GRM2, GRM1 | HTR2C 345/4885DRD2 342/4885HTR2A 249/4885 |
| US-20120022108-A1 | ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | GRM5, GRM2, GRM1 | HTR2C 345/4885DRD2 342/4885HTR2A 249/4885 |
| US-20110112143-A1 | ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | GRM5, GRM2, GRM1 | HTR2C 345/4885DRD2 342/4885HTR2A 249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.